RedHill Biopharma Ltd. Sponsored ADR Stock

$6.91

5.50% day before yesterday

Nasdaq, Dec 27, 10:12 pm CET

ISIN

US7574681034

Symbol

RDHL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

RedHill Biopharma Ltd. Sponsored ADR Stock price

$6.91

-6,043.09 99.89% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

+0.36 5.50%

ISIN

US7574681034

Symbol

RDHL

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$8.81m
Enterprise Value	$-5.06m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	0.19
EV/Sales (TTM) EV/Sales	-0.14
P/S ratio (TTM) P/S ratio	0.25
P/B ratio (TTM) P/B ratio	0.31
Revenue growth (TTM) Revenue growth	-55.76%
Revenue (TTM) Revenue	$35.52m
EBIT (operating result TTM) EBIT	$-35.11m
Free Cash Flow (TTM) Free Cash Flow	$-26.04m
Cash position	$16.15m
EPS (TTM) EPS	$-78.99
Short interest	0.49%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

RedHill Biopharma Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast RedHill Biopharma Ltd. Sponsored ADR:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast RedHill Biopharma Ltd. Sponsored ADR:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from RedHill Biopharma Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '23		+/- %
Revenue	36 36	56% 56% 100%
- Direct Costs	21 21	53% 53% 60%
Gross Profit	14 14	59% 59% 40%
- Selling and Administrative Expenses	38 38	37% 37% 108%
- Research and Development Expense	5.04 5.04	69% 69% 14%
EBITDA	-29 -29	31% 31% -83%
- Depreciation and Amortization	5.65 5.65	68% 68% 16%
EBIT (Operating Income) EBIT	-35 -35	42% 42% -99%
Net Profit	11 11	115% 115% 32%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

RedHill Biopharma Ltd. Sponsored ADR Stock News

Neutral

PRNewsWire

●

19 days ago

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

Heightened geopolitical tensions and Homeland Security concerns call for the development of potential therapies that can be quickly and easily mobilized in the event of a mass casualty nuclear or radiological incident There are currently no known approved therapies for gastrointestinal acute radiation syndrome (GI-ARS) Positive results from new in vivo studies of opaganib as a treatment for GI-...

Neutral

PRNewsWire

●

27 days ago

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill has been awarded a judgment of approximately $8 million plus costs in a summary judgment by the New York Supreme Court in its legal proceedings against Kukbo Co. Ltd The Court dismissed the entirety of Kukbo's counterclaims, ruling in favor of RedHill's demonstrated good faith commitment to the spirit and the letter of the agreements TEL-AVIV, Israel and RALEIGH, N.C. , Dec. 2, 2024 /PR...

Neutral

PRNewsWire

●

2 months ago

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill has been selected to provide a presentation to further elaborate on opaganib's potential to U.S. government representatives at the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense's (JPEO-CBRND) "Host Directed Therapeutics Industry Day" -- Based on reviews, feedback, and discussion, the judges selected for presentation those therapeutics that dem...

More RedHill Biopharma Ltd. Sponsored ADR News

Company Profile

RedHill Biopharma Ltd. is a biopharmaceutical company focusing on the development and commercialization of proprietary drugs for the treatment of gastrointestinal diseases. It operates through the Commercial Operations segment and the Research & Development segment. The Commercial Operations segment covers all areas relating to the commercial sales and operating expenses directly related to that activity and is being performed by the Company's subsidiary in the United States. The Research & Development segment includes all activities related to the research and development of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

Head office	Israel
CEO	Dror Ben-Asher
Employees	53
Founded	2009
Website	www.redhillbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now